ALS Treatment in China: What Patients Can Realistically Expect

Understanding ALS: What We Are Dealing With

ALS — Amyotrophic Lateral Sclerosis — is a progressive neurodegenerative disease affecting upper motor neurons (in the brain's motor cortex) and lower motor neurons (in the spinal cord and brainstem). The result is progressive muscle weakness, atrophy, and eventual paralysis. Respiratory muscle weakness is the primary cause of death, typically within 2–5 years of symptom onset (median).

However, prognosis varies enormously. Some patients follow a rapid course; others live 10+ years (Stephen Hawking lived over 50 years with ALS). Early intervention, proactive management of complications, and optimized multidisciplinary care consistently extend both survival and quality of life.

What Eber Medical Group Can Realistically Offer

1. Slowing the Rate of Muscle Atrophy

Realistic expectation: Systematic rehabilitation — particularly electrical stimulation, robotic mechanotherapy, and targeted resistance exercise within the patient's capacity — does not stop motor neuron death. But it maximizes the function of surviving motor units and delays disuse atrophy. Evidence consistently shows that appropriately dosed exercise (not excessive, which worsens ALS) maintains strength and function for longer.

At Eber, the rehabilitation team individualizes exercise intensity based on ALS Functional Rating Scale (ALSFRS-R) and strength testing. We do not provide cookie-cutter programs.

2. Respiratory Management — Potentially Life-Extending

Realistic expectation: Proactive respiratory management is one of the highest-impact interventions in ALS. Initiating non-invasive ventilation (NIV/BiPAP) at the appropriate time — guided by spirometry showing FVC <50% or symptoms of nocturnal hypoventilation — consistently extends survival by 6–12 months compared to late or no NIV.

Eber's pulmonology team and rehabilitation specialists work together on:

• Baseline and serial spirometry (FVC, FEV1, MEP/MIP)
• NIV titration and mask fitting
• Cough assist device training (mechanical insufflation-exsufflation)
• Suctioning training for caregivers
• Advance care planning discussions (timing of more invasive ventilation if chosen)

3. Bulbar Symptom Management

Realistic expectation: For patients with bulbar-onset ALS (dysarthria, dysphagia), early speech therapy intervention significantly extends the window of safe oral feeding and maintains communication longer. Eber's speech therapists assess swallowing function (videofluoroscopy available), adapt food textures, recommend compensatory swallowing techniques, and introduce augmentative communication (AAC) devices before speech becomes unintelligible.

4. Neuroprotective Pharmacotherapy

Disease-modifying medications with regulatory approval:

• Riluzole (Rilutek): The original ALS disease modifier. Reduces glutamate excitotoxicity. Extends median survival by approximately 2–3 months; effects accumulate over time.
• Edaravone (Radicava): An antioxidant approved for early-stage ALS. Shown to slow functional decline (ALSFRS-R) by approximately 33% in a specific patient subgroup.
• Additional medications are under investigation; Eber's neurologists are current on the latest trial evidence.

5. TCM Neuroprotective Therapy

In TCM, ALS maps to "wei syndrome" (痿证) — atrophy syndrome driven by spleen-kidney Yang deficiency and insufficient nourishment of the sinews and marrow. Eber's TCM physician prescribes individualized treatment combining:

• Moxa therapy: Tonifies spleen and kidney Yang (Guanyuan CV4, Mingmen GV4, Pishu BL20, Shenshu BL23) — improves energy, reduces cold-type fatigue, may modulate immune function
• Acupuncture: Targets sinew channels and motor points — Jianyu (LI15), Quchi (LI11), Hegu (LI4) for upper limb; Huantiao (GB30), Yanglingquan (GB34) for lower limb; Zhusanli (ST36) for spleen-stomach tonification
• Herbal medicine: Spleen-kidney tonifying formulas (Buzhong Yiqi Tang base; Jinque Shen Qi Wan variant) — tailored to pulse/tongue findings. Some herbs have preclinical neuroprotective data (Astragalus, Ligustrum, Cornus).
• Dietary therapy: High-calorie, easily digestible foods per TCM constitution — critically important as ALS patients are at high risk of malnutrition

6. Psychological Support and Caregiver Education

Realistic expectation: Depression and anxiety affect 50–75% of ALS patients. Psychological support — individual counseling, family therapy, support group facilitation — meaningfully improves quality of life even when physical function is declining. Eber's team includes psychologists trained in neurological conditions.

Caregiver training is equally important: family members learn correct positioning, transfer techniques, oral suction, communication board use, and emotional self-care.

What Eber Realistically Cannot Do

Transparency matters. Eber Medical Group cannot:

• Regenerate motor neurons that have already been lost
• Stop the underlying disease process (no current therapy achieves this reliably)
• Guarantee survival or disease trajectory — ALS prognosis varies enormously by subtype, onset, and genetics
• Provide stem cell therapy — we do not offer unproven stem cell treatments for ALS

Summary: Realistic Goals for ALS at Eber Medical Group

Although ALS / MND is a serious, progressive disease, professional neurorehabilitation at Eber Medical Group — using the most advanced technology, the most experienced multidisciplinary team, and the unique integration of Traditional Chinese Medicine — gives patients the maximum realistic possibility of maintaining function, dignity, and quality of life.